Lantheus Holdings, Inc. (NASDAQ:LNTH) Expected to Announce Earnings of $0.70 Per Share

Wall Street analysts predict that Lantheus Holdings, Inc. (NASDAQ:LNTH – Get Rating) will report $0.70 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Lantheus’ earnings, with estimates ranging from $0.67 to $0.71. Lantheus reported earnings per share of $0.11 in the same quarter last year, which would indicate a positive year-over-year growth rate of 536.4%. The company is expected to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Lantheus will report full year earnings of $3.04 per share for the current fiscal year, with EPS estimates ranging from $2.93 to $3.15. For the next financial year, analysts anticipate that the firm will post earnings of $3.33 per share, with EPS estimates ranging from $2.51 to $3.63. Zacks’ EPS averages are a mean average based on a survey of research firms that cover Lantheus.

Lantheus (NASDAQ:LNTH – Get Rating) last posted its earnings results on Friday, April 29th. The medical equipment provider reported $0.97 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.51. The company had revenue of $208.90 million for the quarter, compared to the consensus estimate of $165.30 million. Lantheus had a positive return on equity of 19.83% and a negative net margin of 6.89%. Lantheus’s quarterly revenue was up 125.8% compared to the same quarter last year. During the same period in the previous year, the business earned $0.05 earnings per share.

A number of analysts have commented on the company. B. Riley began coverage on Lantheus in a research report on Monday, May 9th. They set a “buy” rating and a $91.00 target price on the stock. Truist Financial upped their price objective on Lantheus from $77.00 to $94.00 in a research report on Monday, May 2nd. StockNews.com began coverage on Lantheus in a research report on Thursday, March 31st. They issued a “hold” rating on the stock. Zacks Investment Research upgraded Lantheus from a “sell” rating to a “hold” rating and set a $74.00 price objective on the stock in a research report on Tuesday, May 3rd. Finally, SVB Leerink upped their price objective on Lantheus from $34.00 to $75.00 and gave the company an “outperform” rating in a research report on Thursday, February 24th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, Lantheus presently has a consensus rating of “Buy” and an average target price of $83.50.

In related news, CEO Mary Anne Heino sold 43,909 shares of the company’s stock in a transaction on Monday, February 28th. The stock was sold at an average price of $46.50, for a total value of $2,041,768.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Daniel Niedzwiecki sold 1,380 shares of the company’s stock in a transaction on Wednesday, May 18th. The shares were sold at an average price of $64.54, for a total value of $89,065.20. Following the completion of the transaction, the insider now owns 71,143 shares of the company’s stock, valued at $4,591,569.22. The disclosure for this sale can be found here. Insiders sold 136,551 shares of company stock valued at $7,143,905 over the last quarter. Insiders own 1.60% of the company’s stock.

A number of large investors have recently made changes to their positions in LNTH. Wells Fargo & Company MN increased its stake in Lantheus by 79.5% during the second quarter. Wells Fargo & Company MN now owns 63,953 shares of the medical equipment provider’s stock worth $1,767,000 after acquiring an additional 28,329 shares during the last quarter. Morgan Stanley increased its stake in Lantheus by 49.0% during the second quarter. Morgan Stanley now owns 255,027 shares of the medical equipment provider’s stock worth $7,050,000 after acquiring an additional 83,817 shares during the last quarter. Deutsche Bank AG increased its stake in Lantheus by 27.5% during the third quarter. Deutsche Bank AG now owns 56,335 shares of the medical equipment provider’s stock worth $1,448,000 after acquiring an additional 12,155 shares during the last quarter. Swiss National Bank boosted its position in shares of Lantheus by 1.0% in the third quarter. Swiss National Bank now owns 149,154 shares of the medical equipment provider’s stock worth $3,830,000 after buying an additional 1,500 shares during the period. Finally, Barclays PLC boosted its position in shares of Lantheus by 53.8% in the third quarter. Barclays PLC now owns 53,981 shares of the medical equipment provider’s stock worth $1,386,000 after buying an additional 18,875 shares during the period. Institutional investors own 97.14% of the company’s stock.

LNTH traded down $1.00 during trading on Friday, reaching $62.29. 906,088 shares of the stock were exchanged, compared to its average volume of 1,351,692. The business’s 50 day moving average price is $59.12 and its two-hundred day moving average price is $40.62. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.83 and a quick ratio of 1.64. The company has a market capitalization of $4.27 billion, a price-to-earnings ratio of -109.28, a P/E/G ratio of 0.67 and a beta of 0.76. Lantheus has a 1 year low of $19.30 and a 1 year high of $69.74.

About Lantheus (Get Rating)

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 to detect cardiovascular disease; and Gallium-67 to detect various infections and cancerous tumors.

Read More